This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
DOC: Difference between revisions
>Unity Grammatics |
>Larnaca |
||
| (36 intermediate revisions by 11 users not shown) | |||
| Line 1: | Line 1: | ||
{{SummarySheet}} | {{SummarySheet}} | ||
{{SubstanceBox/DOC}} | {{SubstanceBox/DOC}} | ||
'''4-Chloro-2,5-dimethoxyamphetamine''' (also known as '''DOC''') is a lesser-known [[psychoactive class::psychedelic]] substance of the [[chemical class::Substituted amphetamine|amphetamine]] class. It is a member of the [[DOx]] family of psychedelic amphetamines, which are known for their long duration and mixture of psychedelic and stimulant effects. | |||
DOC was first synthesized by a team at the University of Alberta in 1972.<ref name="Coutts1973">{{cite journal|last1=Coutts|first1=R. T.|last2=Malicky|first2=J. L.|year=1973|title=The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM)|journal=Canadian Journal of Chemistry|volume=51|issue=9|pages=1402-1409|doi=10.1139/v73-210|issn=0008-4042|eissn=1480-3291|oclc=02248672}}</ref> However, its usage in humans was not popularized until the 1991 publication [[PiHKAL]] ("Phenethylamines I Have Known And Loved") by [[Alexander Shulgin]].<ref name="PiHKAL">{{cite book|title=PiHKAL: A Chemical Love Story|title-link=PiHKAL|author-link1=Alexander Shulgin|author1=Alexander Shulgin|author2=Ann Shulgin|year=1991|publisher=Transform Press|location=United States|isbn=0963009605|oclc=1166889264|chapter-url=https://erowid.org/library/books_online/pihkal/pihkal064.shtml|chapter=#64. DOC}}</ref> Preceding this, a 1989 forensic analysis of designer amphetamine samples identified DOC in Canadian drug seizures.<ref name="Dawson1989">{{cite journal|first1=B. A.|last1=Dawson|first2=G. A.|last2=Neville|year=1989|title= Identification of Two New “Designer” Amphetamines by NMR Techniques|journal=Canadian Society of Forensic Science Journal|volume=22|issue=2|pages=195-202|doi=10.1080/00085030.198|issn=0008-5030|eissn=2332-1660|oclc=16515635}}</ref> | |||
DOC | DOC is known as a highly dose-sensitive psychedelic that is often sold in powder form or on blotting paper and known for its long duration (over 12-24 hours), strong visual effects, a unique form of [[stimulation]], and a significant body load. | ||
Along with its sensitive dose-response and unusually long duration, many reports also suggest that this substance may be overly difficult to use safely for those who are not already very experienced with [[hallucinogens]]. Therefore it is highly advised to approach this unusually dose-sensitive, and long-lasting [[psychedelic]] substance with the proper amount of precaution and [[harm reduction practices]] if choosing to use it. | Along with its sensitive dose-response and unusually long duration, many reports also suggest that this substance may be overly difficult to use safely for those who are not already very experienced with [[hallucinogens]]. Therefore it is highly advised to approach this unusually dose-sensitive, and long-lasting [[psychedelic]] substance with the proper amount of precaution and [[harm reduction practices]] if choosing to use it. | ||
| Line 14: | Line 11: | ||
==History and culture== | ==History and culture== | ||
{{historyStub}} | {{historyStub}} | ||
DOC was first synthesized by 1972 by Ronald Coutts and Jerry Malicky at the University of Alberta<ref | DOC was first synthesized by 1972 by Ronald Coutts and Jerry Malicky at the University of Alberta.<ref name="Coutts1973" /> While human usage was popularized by the 1991 publication of its synthesis and pharmacology in [[PiHKAL]] ("Phenethylamines I Have Known And Loved")<ref name="PiHKAL" /> by [[Alexander Shulgin]], a 1989 forensic analysis of designer amphetamine samples identified DOC in Canadian drug seizures.<ref name="Dawson1989" /> | ||
==Chemistry== | ==Chemistry== | ||
DOC or 4-chloro-2,5-dimethoxy-amphetamine, is a molecule of the [[substituted amphetamine]] class. Amphetamines are substituted phenethylamines containing a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain and a methyl group bound to the alpha carbon R<sub>α</sub>. DOC contains methoxy functional groups OCH<sub>3</sub> attached to carbons R<sub>2</sub> and R<sub>5</sub> and a chlorine atom attached to carbon R<sub>4</sub> of the phenyl ring. DOC is the amphetamine analogue of the phenethylamine [[2C-C]].<ref> | DOC or 4-chloro-2,5-dimethoxy-amphetamine, is a molecule of the [[substituted amphetamine]] class. Amphetamines are substituted phenethylamines containing a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain and a methyl group bound to the alpha carbon R<sub>α</sub>. DOC contains methoxy functional groups OCH<sub>3</sub> attached to carbons R<sub>2</sub> and R<sub>5</sub> and a chlorine atom attached to carbon R<sub>4</sub> of the phenyl ring. DOC is the amphetamine analogue of the phenethylamine [[2C-C]].<ref name="PiHKAL" /> | ||
DOC is a substituted alpha-methylated phenethylamine, a class of compounds commonly known as amphetamines. The phenethylamine equivalent (lacking the alpha-methyl group) is 2C-C. DOC has a stereocenter and (''R'')-(−)-DOC is the more active stereoisomer. | |||
==Pharmacology== | ==Pharmacology== | ||
{{Further|Serotonergic psychedelic}} | {{Further|Serotonergic psychedelic}} | ||
DOC acts as a selective 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> receptor partial agonist. Its psychedelic effects are mediated via its actions on the 5-HT<sub>2A</sub> receptor. | |||
DOC's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]. However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive. | DOC's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]. However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive. | ||
| Line 29: | Line 30: | ||
|{{effects/physical| | |{{effects/physical| | ||
*'''[[Effect::Stimulation]]''' - DOC is usually reported to be extremely stimulating at levels which are capable of becoming uncomfortable and overwhelming | *'''[[Effect::Stimulation]]''' - DOC is usually reported to be extremely stimulating at levels which are capable of becoming uncomfortable and overwhelming. This can result in a shakiness and unsteadiness of the hands but encouraging one to move around, run, dance, climb and generally engage in physical activities. In comparison, other more commonly used psychedelics such as [[psilocin]] are generally sedating and relaxed. The type of stimulation is generally encouraged but can also present some forcefulness to it. | ||
*'''[[Effect::Spontaneous | *'''[[Effect::Spontaneous bodily sensations]]''' - The "body high" of DOC is manifested as somewhat intense in comparison to most classical psychedelics such as [[LSD]]. The sensation itself can be described as a constantly present yet somewhat mild energetic pins and needles sensation that encompasses a person’s entire body. It is usually felt over every square inch of the skin, but occasionally manifests itself in the form of a continuously shifting tingling sensation that travels up and down the body in spontaneous waves. | ||
**'''[[Effect::Physical euphoria]]''' - It should be noted that this effect is not as reliably | **'''[[Effect::Physical euphoria]]''' - It should be noted that this effect is not as reliably induced as it is with substances like stimulants or entactogens, and can just as easily manifest as physical discomfort without any apparent reason. DOC and other psychedelic amphetamines tend to lean towards physical dysphoria more so than other psychedelics. | ||
*'''[[Effect::Changes in felt bodily form]]''' | *'''[[Effect::Changes in felt bodily form]]''' | ||
*'''[[Effect::Bodily control enhancement]]''' | *'''[[Effect::Bodily control enhancement]]''' | ||
*'''[[Effect::Tactile enhancement]]''' - Feelings of enhanced tactile sensation are consistently present at low to moderate levels throughout most DOC experiences. | *'''[[Effect::Tactile enhancement]]''' - Feelings of enhanced tactile sensation are consistently present at low to moderate levels throughout most DOC experiences. | ||
*'''[[Effect::Nausea]]''' - Mild to extreme nausea is reported when consumed in moderate to high dosages and either passes once the person has vomited or gradually fades by itself as the peak sets in. | *'''[[Effect::Nausea]]''' - Mild to extreme nausea is reported when consumed in moderate to high dosages and either passes once the person has vomited or gradually fades by itself as the peak sets in. | ||
*'''[[Effect::Vasoconstriction]]''' - This effect is usually only present at higher dosages, but can be particularly uncomfortable when it manifests, and may persist throughout the main duration of the experience. | *'''[[Effect::Vasoconstriction]]''' - This effect is usually only present at higher dosages, but can be particularly uncomfortable when it manifests, and may persist throughout as well as after the main duration of the experience. | ||
*'''[[Effect::Increased blood pressure]]''' | *'''[[Effect::Increased blood pressure]]'''{{citation needed}} | ||
*'''[[Effect::Increased heart rate]]''' | *'''[[Effect::Increased heart rate]]'''{{citation needed}} | ||
*'''[[Effect::Appetite suppression]]''' | *'''[[Effect::Appetite suppression]]''' | ||
*'''[[Effect::Increased perspiration]]''' | *'''[[Effect::Increased perspiration]]''' | ||
*'''[[Effect::Muscle contractions]]''' | *'''[[Effect::Muscle contractions]]''' | ||
*'''[[Effect::Muscle spasms]]''' | *'''[[Effect::Muscle spasms]]''' | ||
*'''[[Effect::Muscle cramps]]''' | |||
*'''[[Effect::Difficulty urinating]]''' | *'''[[Effect::Difficulty urinating]]''' | ||
*'''[[Effect::Dehydration]]''' | *'''[[Effect::Dehydration]]''' | ||
*'''[[Effect::Dry mouth]]''' | *'''[[Effect::Dry mouth]]''' | ||
*'''[[Effect::Temperature regulation suppression]]''' - This effect is more prominent than it is with other psychedelics like [[LSD]]. | |||
*'''[[Effect::Temperature regulation suppression]]''' - This effect is more prominent than it is with [[LSD]]. | |||
*'''[[Effect::Diarrhea]]''' | *'''[[Effect::Diarrhea]]''' | ||
*'''[[Effect::Teeth grinding]]''' | *'''[[Effect::Teeth grinding]]''' | ||
*'''[[Effect::Restless legs]]''' | |||
*'''[[Effect::Pupil dilation]]''' | *'''[[Effect::Pupil dilation]]''' | ||
*'''[[Effect:: | *'''[[Effect::Increased salivation]]''' | ||
*'''[[Effect::Seizure]]''' - This is a rarely observed effect but is known to happen in those who are presumably predisposed to them, especially while in physically taxing conditions such as being dehydrated, undernourished, overheated, or generally fatigued.{{citation needed}} | *'''[[Effect::Seizure]]''' - This is a rarely observed effect but is known to happen in those who are presumably predisposed to them, especially while in physically taxing conditions such as being dehydrated, undernourished, overheated, or generally fatigued.{{citation needed}} | ||
| Line 57: | Line 59: | ||
{{effects/visual| | {{effects/visual| | ||
The visuals of DOC are commonly described as being very | The visuals of DOC are commonly described as being very simplistic, cartoon-like and linear, when compared to [[DOB]] or [[LSD]]. | ||
====Enhancements==== | ====Enhancements==== | ||
| Line 76: | Line 78: | ||
====[[Effect::Geometry]]==== | ====[[Effect::Geometry]]==== | ||
The visual geometry | The visual geometry encountered on DOC can be described as more similar in appearance to that of [[mescaline]] than that of [[ayahuasca]], [[psilocybin mushrooms]] or [[LSD]]. It can be comprehensively described through its [[Visual_effects:_Geometry#Variations|variations]] as intricate in complexity, abstract in form, synthetic in feel, structured in organization, brightly lit, multicolored in scheme, glossy in shading, sharp in edges, large in size, fast in speed, smooth in motion, equally rounded and angular in its corners, non-immersive in depth and consistent in intensity. At higher dosages, this geometry is significantly more likely to result in states of [[Effect::8B Geometry|level 8B]] visual geometry over [[8A Geometry|level 8A]]. | ||
====Hallucinatory states==== | ====Hallucinatory states==== | ||
DOC and other [[substituted amphetamines]] produce a full range of high-level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used [[psychedelic]]s | DOC and other [[substituted amphetamines]] produce a full range of high-level hallucinatory states in a fashion that is more or less consistent and reproducible than that of many other commonly used [[psychedelic]]s. These effects include: | ||
*'''[[Effect::Transformations]]''' | *'''[[Effect::Transformations]]''' | ||
*'''[[Effect::Internal | *'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - In comparison to other [[psychedelic]]s such as [[LSD]], DOC is extremely high in internal hallucinations when approaching higher dosages. They are more common within dark environments and can be comprehensibly described through its [[Internal_hallucinations#Variations|variations]] as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, [[geometry]]-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme. | ||
*'''[[Effect:: External hallucinations]]''' - These are often present during the comedown and can include [[shadow people]], among other indescribable beings. These external hallucinations are often lucid, interactive, autonomous, and robust. As [[sleep deprivation]] and [[stimulant psychosis]] surface, a [[trip sitter]] should accompany individuals sensitive to stimulants for the last part of the comedown. The visual effects of psychosis have been reported to blend into the psychedelic visuals around the 16-24 hour mark, sometimes accompanied by auditory hallucinations. | *'''[[Effect:: External hallucinations]]''' - These are often present during the comedown and can include [[shadow people]], among other indescribable beings. These external hallucinations are often lucid, interactive, autonomous, and robust. As [[sleep deprivation]] and [[stimulant psychosis]] surface, a [[trip sitter]] should accompany individuals sensitive to stimulants for the last part of the comedown. The visual effects of psychosis have been reported to blend into the psychedelic visuals around the 16-24 hour mark, sometimes accompanied by auditory hallucinations. | ||
| Line 92: | Line 94: | ||
The total sum of these cognitive components regardless of the setting generally includes: | The total sum of these cognitive components regardless of the setting generally includes: | ||
*'''[[Effect::Anxiety]]''' & '''[[Effect::Paranoia]]''' - This effect is not as common at low to moderate doses and is less likely to occur when the basic rules of [[set and setting]] are taken into account. It should be noted that this inconsistently induced effect is seemingly more likely to manifest when used with [[cannabis]]. This combination should be used with extreme caution if one is not experienced with psychedelics, meaning that the user should adequately pace themselves with a fraction of their usual amount. It is commonly reported that psychedelics can to a certain extent counteract some of the perceived mental cloudiness or intoxicating effects of THC causing the user to in turn use more cannabis than is needed which can often lead to an overwhelmingly anxious and paranoid headspace which can trigger a [[bad trip|"bad trip"]]. | |||
*'''[[Effect::Conceptual thinking]]''' | *'''[[Effect::Conceptual thinking]]''' | ||
*'''[[Effect::Thought acceleration]]''' | *'''[[Effect::Thought acceleration]]''' | ||
*'''[[Effect::Thought connectivity]]''' | *'''[[Effect::Thought connectivity]]''' | ||
*'''[[Effect::Empathy, affection, and sociability enhancement]]''' - This component is typically manifested only in the context of social settings in which one is within the company of others, and only at lower, non-impairing doses. These feelings of sociability, affection, and empathy tend to be weaker and less consistent than those produced by substances such as [[MDMA]] and [[2C-B]], but can still prove strong enough to provide long-lasting therapeutic effects. | *'''[[Effect::Empathy, affection, and sociability enhancement]]''' - This component is typically manifested only in the context of social settings in which one is within the company of others, and only at lower, non-impairing doses. These feelings of sociability, affection, and empathy tend to be weaker and less consistent than those produced by substances such as [[MDMA]] and [[2C-B]], but can still prove strong enough to provide long-lasting therapeutic effects. | ||
*'''[[Effect::Cognitive euphoria]]''' | *'''[[Effect::Cognitive euphoria]]''' | ||
*'''[[Effect::Analysis enhancement]]''' - This effect is consistent in its manifestation and [[outrospection]] dominant. | *'''[[Effect::Analysis enhancement]]''' - This effect is consistent in its manifestation and [[outrospection]] dominant. | ||
*'''[[Effect::Novelty enhancement]]''' | *'''[[Effect::Novelty enhancement]]''' | ||
*'''[[Effect::Immersion enhancement]]''' | *'''[[Effect::Immersion enhancement]]''' | ||
| Line 107: | Line 108: | ||
**'''[[Effect::Laughter fits]]''' - This can manifest prominently during a DOC experience, particularly during the [[Duration#Come up|come up]] phase, often resulting in bouts of uncontrollable giggles and laughter that can form a feedback loop if around others who are also under the influence. | **'''[[Effect::Laughter fits]]''' - This can manifest prominently during a DOC experience, particularly during the [[Duration#Come up|come up]] phase, often resulting in bouts of uncontrollable giggles and laughter that can form a feedback loop if around others who are also under the influence. | ||
*'''[[Effect::Memory suppression]]''' | *'''[[Effect::Memory suppression]]''' | ||
**'''[[Effect::Ego death]]''' | **'''[[Effect::Ego death]]''' - While DOC is technically able to produce states of ego dissolution, it tends to more often than not develop only in extremely high doses, with grave physical and mental side effects being apparent and is often of a terrifying nature. | ||
*'''[[Effect::Increased libido]]''' | *'''[[Effect::Increased libido]]''' | ||
*'''[[Effect::Time distortion]]''' | *'''[[Effect::Time distortion]]''' | ||
| Line 117: | Line 118: | ||
*'''[[Effect::Auditory enhancement]]''' | *'''[[Effect::Auditory enhancement]]''' | ||
*'''[[Effect::Auditory distortion]]''' | *'''[[Effect::Auditory distortion]]''' | ||
*'''[[Effect::Auditory | *'''[[Effect::Auditory hallucination]]''' | ||
}} | }} | ||
| Line 136: | Line 137: | ||
{{#ask: [[Category:DOC]][[Category:Experience]]|format=ul|Columns=1}} | {{#ask: [[Category:DOC]][[Category:Experience]]|format=ul|Columns=1}} | ||
Additional experience reports can be found here: | Additional experience reports can be found here: | ||
* [https://erowid.org/experiences/subs/exp_DOC.shtml Erowid Experience Vaults: DOC] | |||
*[https://erowid.org/experiences/subs/exp_DOC.shtml Erowid Experience Vaults: DOC] | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
| Line 142: | Line 144: | ||
The toxicity and long-term health effects of recreational DOC use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. | The toxicity and long-term health effects of recreational DOC use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. | ||
Anecdotal | Anecdotal reports suggest that there are no negative health effects attributed to simply trying DOC by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption. | ||
Medical literature reports multiple physical complications associated with the use of DOC. An individual's cause of death was reported as DOC toxicity and confirmed with GC-MS in the Journal of Analytical Toxicology.<ref> | Medical literature reports multiple physical complications associated with the use of DOC. An individual's cause of death was reported as DOC toxicity and confirmed with GC-MS in the Journal of Analytical Toxicology.<ref>{{cite journal|pmid=25217551|doi=10.1093/jat/bku087|title=A Fatal Intoxication of 2,5-Dimethoxy-4-Chloroamphetamine: A Case Report|first1=R. Y.|last1=Barnett|first2=D. D.|last2=Baker|first3=N. E.|last3=Kelly|first4=C. E.|last4=McGuire|first5=T. C.|last5=Fassette|first6=J. M.|last6=Gorniak|year=2014|volume=38|issue=8|pages=589-591|journal=Journal of Analytical Toxicology|issn=0146-4760|eissn=1945-2403|oclc=02942106}}</ref> Seizures have been associated with the use of DOC in another medical journal.<ref>{{cite journal|pmid=25553227|pmc=4272348|doi=10.1177/1941874414528939|title=Hallucinogens Causing Seizures? A Case Report of the Synthetic Amphetamine 2,5-Dimethoxy-4-Chloroamphetamine|first1=M. J.|last1=Burish|first2=K. L.|last2=Thoren|first3=M.|last3=Madou|first4=S.|last4=Toossi|first5=M.|last5=Shah|year=2015|volume=5|issue=1|pages=32-34|issn=1941-8752|oclc=969758598|journal=The Neurohospitalist}}</ref> | ||
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance. | It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance. | ||
===Tolerance and addiction potential=== | ===Tolerance and addiction potential=== | ||
DOC is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating. | DOC is [[Addiction potential::not habit-forming]], and the desire to use it can actually decrease with use. It is most often self-regulating. | ||
Tolerance to the effects of DOC is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). DOC presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of DOC all psychedelics will have a reduced effect. | |||
===Overdose=== | |||
{{DOxOD}} | |||
===Dangerous interactions=== | ===Dangerous interactions=== | ||
{{DangerousInteractions/Intro}} | {{DangerousInteractions/Intro}} | ||
{{DangerousInteractions/Psychedelics}} | |||
==Legal status== | |||
Internationally, DOC was added to the UN Convention on Psychotropic Substances as a Schedule II controlled substance in March 2020.<ref>{{cite web|url=https://www.unodc.org/LSS/Announcement/Details/021820a0-8746-42a4-9ee3-47ce50b30ca3|date=December 2019|title=WHO: World Health Organization recommends 12 NPS for scheduling|access-date=October 16, 2020}}</ref><ref>{{cite web|url=https://www.who.int/news/item/18-03-2020-c-n-d-accepts-all-w-h-o-recommendations-from-42nd-e-c-d-d|title=CND accepts all WHO recommendations on the control of several psychoactive substances from the 42nd ECDD meeting|date=March 18, 2020|publisher=World Health Organization (WHO)|access-date=October 16, 2020}}</ref> | |||
*'''Austria''': DOC is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).{{citation needed}} | |||
*'''Brazil''' | *'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>{{cite web|title=RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016|publication-date=December 5, 2016|language=pt|access-date=January 8, 2020|publisher=Agência Nacional de Vigilância Sanitária (Anvisa) [National Sanitary Surveillance Agency]|url=http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7}}</ref> | ||
*'''Denmark | *'''Canada''': DOC is Schedule I in Canada, making it illegal to sell, buy, or possess, without a valid legal exemption.<ref>{{cite web|url=http://laws-lois.justice.gc.ca/eng/acts/C-38.8/|title=Controlled Drugs and Substances Act (S.C. 1996, c. 19)|access-date=September 30, 2020|publisher=Government of Canada}}</ref> | ||
*'''Finland:''' | *'''China''': As of October 2015 DOC is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html|title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=国家食品药品监督管理总局 [China Food and Drug Administration]|date=September 27, 2015 |language=Chinese| accessdate=1 October 2015}}</ref> | ||
*'''Israel | *'''Denmark''': DOC is a Schedule I drug in Denmark.{{citation needed}} | ||
*'''New Zealand | *'''Finland''': DOC is illegal to possess, produce and sell in Finland.{{citation needed}} | ||
*''' | *'''Germany''': DOC is controlled under Anlage I BtMG<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> (''Narcotics Act, Schedule I'') as of February 1, 1997.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl197s0065.pdf|title=Neunte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 1997 Teil I Nr. 5|page=65|publication-date=January 31, 1997|language=de|issn=0341-1095|date=January 28, 1997}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: § 29|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> | ||
*''' | *'''Israel''': The possession, production and sale is illegal.{{citation needed}} | ||
*'''United Kingdom | *'''Latvia''': DOC is a Schedule I controlled substance.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref> | ||
*'''United States | *'''New Zealand''': DOC is a Class C drug in New Zealand.{{citation needed}} | ||
*'''Netherlands:''' Possession, production and sale is illegal. | |||
*'''Switzerland''': DOC can be considered a controlled substance as a defined derivative of a-Methylphenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | |||
*'''Turkey:''' DOC is a classed as drug and is illegal to possess, produce, supply, or import.<ref>{{cite web|title=Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742|url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm|publisher=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication]|publication-date=January 25, 2014|date=December 16, 2013|language=tr}}</ref><ref>{{cite web|title=Kararnamenin Eki: Liste|url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf|publisher=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication]|publication-date=January 25, 2014|date=December 16, 2013|language=tr|id=2013/5742|work=Resmî Gazete, Sayı: 28893}}</ref> | |||
*'''United Kingdom''': DOC is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=August 20, 2020|publisher=UK Government}}</ref> | |||
*'''United States''': DOC is technically not scheduled in the United States, but could be considered an analogue of DOM or DOB and may therefore be considered a Schedule I drug under the Federal Analogue Act.{{citation needed}} | |||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Psychedelics]] | *[[Psychedelics]] | ||
*[[DOx]] | *[[DOx]] | ||
*[[DOB]] | |||
*[[DOI]] | |||
==External links== | ==External links== | ||
*[http://en.wikipedia.org/wiki/2,5-Dimethoxy-4-chloroamphetamine DOC (Wikipedia)] | *[http://en.wikipedia.org/wiki/2,5-Dimethoxy-4-chloroamphetamine DOC (Wikipedia)] | ||
*[http://www.erowid.org/chemicals/doc/doc.shtml DOC (Erowid Vault)] | *[http://www.erowid.org/chemicals/doc/doc.shtml DOC (Erowid Vault)] | ||
*[https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=64 DOC (PiHKAL / Isomer Design)] | *[https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=64 DOC (PiHKAL / Isomer Design)] | ||
===Discussion=== | ===Discussion=== | ||
*[http://www.bluelight.org/vb/threads/286886-The-Big-amp-Dandy-DOC-Thread-(Part-1) The Big & Dandy DOC Thread (Part 1) (Bluelight)] | *[http://www.bluelight.org/vb/threads/286886-The-Big-amp-Dandy-DOC-Thread-(Part-1) The Big & Dandy DOC Thread (Part 1) (Bluelight)] | ||
| Line 190: | Line 203: | ||
[[Category:Psychoactive substance]] | [[Category:Psychoactive substance]] | ||
[[Category:Psychedelic]] | [[Category:Psychedelic]] | ||
[[Category:DOx]] | |||
[[Category:Research chemical]] | |||
{{#set:Featured=true | {{#set:Featured=true | ||
|RN= | |RN= | ||